Baicalein for Liver Health

Research suggests that baicalein and its glycoside form baicalin have demonstrated consistent liver-protective effects across a range of experimental conditions, including fatty liver disease, liver fibrosis, alcoholic liver injury, acetaminophen-induced damage, and acute liver failure, with all available studies pointing in a supportive direction. Studies indicate these compounds appear to work through multiple distinct biological mechanisms — including reducing inflammation, countering oxidative stress, promoting the death of scar-forming stellate cells via ferroptosis, reprogramming immune cells toward anti-inflammatory states, and activating cellular defense pathways such as Nrf2 and PINK1/Parkin — suggesting broad rather than single-target activity. The body of evidence consists entirely of preclinical research, meaning animal models, cell culture experiments, zebrafish studies, and narrative reviews, with no randomized controlled trials or clinical trials in humans identified among the available literature. This distinction is important: while the mechanistic findings are detailed and internally consistent across studies, it remains unknown whether these effects translate to humans, and further clinical investigation would be needed before any conclusions about therapeutic benefit in people could be drawn.